FHTX

Foghorn TherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

FHD-909 is progressing through Phase 1 with Lilly, while the company reports additional preclinical pipeline progress and cash runway into the first half of 2028 [#SEC-8K-2026-05-07]. Multiple 2027 IND opportunities could broaden the pipeline.

Posture

Constructive

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite.

What can break

Biotech dilution or financing risk remains material despite reported cash runway into the first half of 2028.

Momentum

Value

Sentiment

N/A

Setup hits (3d)

— · Net —

AI TargetsBase $5.60 · Bull $9.50 · Bear $3.20

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-07-19 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade A · Constructive

Confidence Medium · Net —

Target $11.44

Why

Momentum97 · Δ7d -

Value41 · Δ7d -0.1

SentimentN/A · Δ7d -

So what

Strength-led posture. Favor watchlist adds and disciplined entries.

Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits

Lead driver: Momentum · See technicals

Momentum

40% active weight

Current posture

7d trendFlat

Δ7d

Δ21d

Value

60% active weight

Current posture

7d trendFlat

Δ7d

-0.1

Δ21d

0.0

Sentiment

N/A

Coverage pending

No current score

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Why this grade

Composite grade A. Momentum 97.3 / Value 41.1

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$304.73M

Beta

3.02

Shares Out

58.71M

P/E (TTM) · Derived

-4.4

P/S (TTM)

11.49

P/FCF (TTM) · Derived

-3.74

Rev YoY

-45.1%

EPS YoY

-4.6%

Gross Margin

+89.9%

Op Margin

-352.9%

Net Debt

-$118.87M

Current Ratio

2.92

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology